The PhorMed offering is now closed and is no longer accepting investments.

PhorMed

Utilizing Gene Repair Therapy to Treat Diseases

PhorMed

Utilizing Gene Repair Therapy to Treat Diseases

Century City, CA
Biotechnology
Health Tech
PhorMed is a Biotech Company paving the way in the advancement of a Gene Repair Therapy with our lead drug internally called RP-323. Our drug has the ability to repair cells allowing the body to recover. We are looking to treat a variety of disorders such as Parkinson’s disease, Acute Myeloid Leukemia, Hodgkin’s Lymphoma and Acute Respiratory Distress Syndrome, caused by COVID-19

$240,443

raised
$2,515,255
previously crowdfunded
207
Investors
$51.6M
Valuation
$1.00
Price per Share
$500.00
Min. Investment
Common
Shares Offered
Equity
Offering Type
$2.15M
Offering Max
0
Days Left

$240,443

raised
$2,515,255
previously crowdfunded
207
Investors
$51.6M
Valuation
$1.00
Price per Share
$500.00
Min. Investment
Common
Shares Offered
Equity
Offering Type
$2.15M
Offering Max
0
Days Left
This offering ended on August 18, 2022 and is no longer accepting investments.

Reasons to Invest


  • Our goal is to replace CHEMOTHERAPY treatment with an ALTERNATIVE TREATMENT that, if we make it to market, would NOT REQUIRE HOSPITAL STAYS in most cases.


  • Our drug can potentially treat multiple diseases resulting in a greater chance of success and larger market potential, a combined overall market potential of over $12 billion per year.


  • We have a highly credentialed team. Our key personnel and advisory board members have compiled a combined 565 peer reviewed publications and abstracts. PhorMed has raised over $2.5 million and gained more than 4,100 total shareholders, and 8,800+ followers.

Overview


Discovering new approaches to therapy in the field of Genomic Medicine


PhorMed is a clinical stage biopharmaceutical company, utilizing Gene Repair Therapy to develop our drug RP-323, to treat diseases such as Parkinson’s disease, Acute Myeloid Leukemia, Hodgkin’s Lymphoma and ARDS, caused by COVID-19. PhorMed is pre-revenue and does not currently have a product on the market.



A number of indications are under development which are all categorized as inflammatory disorders. It has been determined that RP-323 is active along specific cell lines, being able to target damaged or mutated cells due to cancer, viruses, and a variety of other factors.


Our studies include cancer cells, blood cells, and, as a result of its special ability to pass through the Blood Brain Barrier (BBB), neurological cells. Because of RP-323’s wide range of activity, the company has been able to build a broad platform from a single molecule. 


The company is working on a treatment for Parkinson’s disease that we believe is in line to become one of the top innovative therapies. RP-323 is also targeted to be a first-line treatment in Oncology, Neurology, and Anti-Virus. The company’s mission is to treat unmet medical needs by treating the cause, and in some cases, the symptom. 



This is accomplished through differentiation, RP-323’s ability to repair the DNA of damaged or mutated cells; immunotherapy, boosting the body’s immune system through cytokine induction; and by stem cell signaling and proliferation, stimulating cell division once the cell is repaired and functioning properly. All of these mechanisms work in unison allowing the body to heal and return to a healthy condition.


Five indications are presently in the pipeline and the company will continue to expand through its continued dedication in research and development. We are committed to the highest standards of scientific excellence and integrity to accomplish these goals for our patients and society. 

the problem


Problematic CHEMOTHERAPY as a treatment or at times NO AVAILABLE OPTIONS


Patient options are frequently limited and at times no known effective options are available.  


With patients suffering from Acute Myeloid Leukemia (AML) or Hodgkin’s Lymphoma (HL), chemotherapy has been the traditional option which is well known to have harmful or lethal side effects, while those with Parkinson’s disease (PD) and Acute Respiratory Distress Syndrome (ARDS), caused by COVID-19 are faced with no realistic treatment options. PhorMed is attempting to offer NEW FIRST-LINE TREATMENTS in these areas allowing patients new hope. (source, source, source, source)



the solution


Our goal is to REPLACE CHEMOTHERAPY in selected Oncology markets and offer new options for all diseases we are attempting to treat


We are looking to offer new treatments for AML, HL, PD, and ARDS caused by COVID-19. Our goal is to make faster acting treatments that are safer for patients, and to make chemotherapy obsolete in our selected markets.


We focus on treating diseases through Gene Repair Therapy


RP-323 utilizes Gene Repair Therapy to target damaged or mutated cells and repair a broad range of cell types. Our technology focuses on the root cause, aiming to fix the cellular damage on a molecular level. 

 

The drug will be administered through intravenous infusion.


THE Market



These deadly diseases are widespread


The world market for drugs treating HL is projected to post a compound annual growth rate (CAGR) of 14.75% for the forecast period of 2022-2026.  The same projections expect the market to reach $1.85 billion by 2026.

 

The CAGR of the AML market is expected to be around 14% over the next five years, and is expected to top $2.22 billion by 2026.

 

The PD world drug market is expected to reach $8.38 billion at CAGR of 8.1% by 2026.


Combined, the total annual market for three of our drug's potential uses could reach close to $12.45 billion by 2026.

 

The COVID-19 market is still to be determined. 


Initial studies have shown our treatments are non-toxic with limited side effects.  


Chemotherapy has long-lasting and potentially devastating side effects and can severely damage and kill healthy cells. 

 

Depending on the severity of a disease when our drug is administered, a majority of treatment recipients will not be required to have hospital stays thanks to the limited side effects and unobtrusive nature of the drug. We believe our treatment will be a safer and non-toxic alternative for a variety of applications including cancer, viruses and neurological disorders. 



OUR TRACTION


Our drug has been proven to be safe by the FDA in early studies


Our drug has been found to be safe for use in humans after the completion of the Phase 1 study. We are allocating a large majority of our funds towards clinical research and are actively proceeding with next steps in clinical research for all our indications. 


RP-323 originally conducted a Phase I trial in 2004-2005. For human FDA trials, there are only three phases prior to entering into the marketplace. Those are Phase 1, Phase 2, Phase 3. Once Phase 1 is complete, the FDA may require an abbreviated safety phase to be included within the Phase 2 study which they call phase 1/2 or I/II. The 1 (I) portion of 1/2 (I/II) is an abbreviated safety step. Once the abbreviated safety step is completed companies move directly to starting Phase 2 (II). As of 2022, PhorMed is currently in phase 1/2 (I/II). We are not currently active in a trial at this time however we are in preparation for this next phase.

 

With your help and proper funding, we expect to eventually complete Phase 2 in all our clinical trials and move into the last stages of testing and finally into the hands of patients who need better options. 



Why invest


Help us modernize the medical industry by making medicine safer and less costly


We are driven to replace Chemotherapy as a first-line treatment offering doctors and patients better options.


We are looking to offer patients a safe and effective way to better health and treatment methods with fewer side effects. We strive to make medical treatment less costly and available to all by reducing or eliminating the need for hospital stays. 


We have an opportunity to improve the path patients take to recovery. With your help, we can make chemotherapy a thing of the past.

 

We believe our technology is the future of medicine. With your financial support we can pave the way to a healthier future with lower medical costs by eliminating or reducing the need for hospital stays, and moving medicine forward into modern times.


Offering Summary


Company

:

Phormed Inc

Corporate Address

:

1999 Avenue of the Stars, #1100, Century City, CA 90067

Offering Minimum

:

$10,000.00

Offering Maximum

:

$2,150,494.00

Minimum Investment Amount

(per investor)

:

$500.00











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

10,000

Maximum Number of Shares Offered

:

2,150,494

Price per Share

:

$1.00

Pre-Money Valuation

:

$51,647,023.00











*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Investment Incentives and Bonuses*

Time-Based:

First Week

Invest within the first week and receive 20% bonus shares.

Second Week

Invest within the first two weeks and receive 15% bonus shares.

Third Week

Invest within the first three weeks and receive 10% bonus shares.

Fourth Week

Invest within the first four weeks and receive 5% bonus shares.

Amount-Based:

$1,000+ | 5% Bonus Shares

Invest $1,000+ to receive 5% bonus shares & access to our Investor Club which allows you to vote on drug names, and receive special investor updates.

$5,000+ | 10% Bonus Shares

Invest $5,000+ to receive 10% bonus shares & access to our Investor Club.

$10,000+ | 15% Bonus Shares

Invest $10,000+ to receive 15% bonus shares & access to our Investor Club.

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

PhorMed, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.00 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $100. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and the 10% Loyalty Bonus Perk for all previous Crowdfunding offering 1 investors on StartEngine in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative. Any expense labeled “Travel and Entertainment”.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$183,724.00 USD
$340,922.00 USD
Cash And Cash Equivalents
$105,694.00 USD
$109,844.00 USD
Accounts Receivable
$0.00 USD
$0.00 USD
Short Term Debt
$227,264.00 USD
$363,294.00 USD
Long Term Debt
$0.00 USD
$0.00 USD
Revenues And Sales
$0.00 USD
$0.00 USD
Costs Of Goods Sold
$0.00 USD
$0.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
-$573,854.00 USD
-$948,160.00 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

Campaign Closing in a Few Hours!

about 2 months ago

Campaign Closing Today. Last Day Left to Invest in PhorMed.

about 2 months ago

Campaign Closing Tomorrow!

about 2 months ago

2 Days Left to Invest in PhorMed!

about 2 months ago

3 Days Left to Invest in PhorMed!

about 2 months ago

4 Days Left to Invest in PhorMed!

about 2 months ago

PHORMED RECEIVES $700,000 FROM ANGEL INVESTOR

about 2 months ago



August 12, 2022

 

The company received a generous investment of $700,000 from one investor through a private placement. These funds will be used to advance the company’s Phase 2 Human Clinical Studies, study drug manufacturing, and expand the company’s pipeline with the filing of a new patent application, the indication to be announced soon. “I would like to thank our investor for their generous investment. The company will benefit with more working capital tracking us along a faster path to our next milestone”, said Ben Chang, CEO.

5 Days Left to Invest in PhorMed!

about 2 months ago

6 Days Left to Invest in PhorMed!

about 2 months ago

PHORMED PARTNERS WITH WUXI BIOLOGICS TO MANUFACTURE PHASE 2 STUDY DRUG FOR ARDS

about 2 months ago

 

                                                                                

August 10, 2022

 

We are pleased to announce our partnership with WuXi Biologics. An agreement was signed today engaging WuXi for their manufacturing services. They have been contracted to produce a new batch of study drug, RP-323, for the upcoming Phase 2 Human Clinical Trials in Acute Respiratory Distress Syndrome (ARDS). “I share my team’s excitement about our new partnership with WuXi. Being a full-service provider, I look forward to the potential future expansion of our partnership, from manufacturing to all aspects of our clinical study needs,” said Ben Chang (CEO).

 

  

Icon

Description automatically generated with medium confidence            A picture containing diagram

Description automatically generated

 

 

About WuXi:

 

WuXi (WUXAY), is a publicly traded company with a $40 Billion market cap. They are a global pharmaceutical, biopharmaceutical, and medical device company employing nearly 40,000 people worldwide and considered one of the largest global providers of R&D and manufacturing services with operations across Asia, Europe, and North America.

7 Days Left to Invest in PhorMed!

about 2 months ago

8 Days Left to Invest in PhorMed!

about 2 months ago

9 Days Left to Invest in PhorMed!

about 2 months ago

10 Days Left to Invest in PhorMed!

about 2 months ago


11 Days Left to Invest in PhorMed!

about 2 months ago


The founder has 125 peer reviewed publications, and we are looking to expand that with this new discovery that RP-323 assists in treating ARDS.

12 Days Left to Invest in PhorMed!

about 2 months ago


We are closing this campaign to focus more of our efforts in moving our ARDS study into Phase 2. Thanks to all those who have supported us in the last 2 campaigns.

Q&A About ARDS Phase 2 Trials

2 months ago

There was a question asked yesterday, and we wanted to share the answer since others may be wondering the same thing.

The question was how we bypass a Phase 1 Human Study after just completing animal studies. Here is our reply:


Thank you for your question, and we am happy to clarify. We are working with a ‘platform technology’, which in our case ‘platform’ represents the same study drug, RP-323, having a number of potential uses. Due to this, we have the benefit of Phase I human trials completed in previous studies where RP-323 has been found to be safe for use in humans. Similar to what we have done in AML and what we are doing in Hodgkin’s Lymphoma, we will be applying for a Phase II in ARDS. At times, like our AML study, the FDA may request a phase 1/2, but a phase 1 is not required. This is one of the many benefits of platform technologies of this type. We have a greater chance of reaching the ultimate goal, which is drug approval for RP-323, having more shots at our target.


[End Reply]


Moving forward, with regard to our ARDS studies, we have already started the interview process of selecting a Contract Research Organization (CRO). They help with Phase 2 Human Trial protocol design and FDA communications and submissions. We are also in conversation with our existing clinical trial partners about their involvement in conducting the phase 2 trial. 


We will post more updates when partnerships are solidified. Hope this update has been helpful.



All the best,


From The PhorMed Team 

Logo, company name

Description automatically generated


CHECK OUT OUR LATEST PRESS RELEASE

2 months ago

We are pleased to announce that a Press Release was published today discussing the exciting, positive, and new discoveries from our ARDS studies. 

 


Here is a sample of what was posted:

PhorMed Inc, a Nevada Corporation (“PhorMed” or the “Company”), is a privately held clinical stage biopharmaceutical company. The Company’s study drug RP-323 is in an on-going acute respiratory distress syndrome (ARDS) study.  ARDS is a lung disorder where fluid collects in the air sacs of the lungs, depriving organs of oxygen. These studies have generated positive results showing RP-323 significantly reduces the influx of inflammatory cells into the lungs thereby limiting damage to the lungs. In addition, RP-323 has shown the ability to block over-active/over-productive pro-inflammatory cytokines including the following interleukins: IL-1, IL-2, IL-9 and IL-15. These interleukins have been shown to be key effectors that comprise the “cytokine storm syndrome” (CSS) consistently observed in severe ARDS associated with COVID-19 and other respiratory infections, including influenza and bacterial pneumonia.

 

ARDS presents in a variety of ways including sudden acute respiratory syndrome (SARS).  In severe and fatal ARDS, disease severity is directly associated with the extent of inflammatory cell (neutrophil and macrophage) infiltration into the lungs.  When ARDS occurs, these inflammatory cells are profoundly elevated in the blood vessels, alveoli and other lung tissue. This results in congestion, hypoxia, vascular destruction and thrombosis (clotting), swelling, and is reflected in histology in ARDS tissue.


These initial ARDS mouse study results demonstrate that RP-323 safely and effectively reduces pulmonary inflammation. The ARDS animal system that we used is a validated model that is predictive of clinical drug efficacy and widely accepted in the industry. This study therefore represents a milestone advancement towards the Company’s goal of initiating human clinical trials of RP-323 for treating ARDS and COVID-19 related lung disorders.

 

Expanding on these initial ARDS study results, PhorMed plans to continue its ARDS studies and, in parallel, to further advance its RP-323 human drug development platform by filing a Phase 2 IND application with the USFDA.

 

About PhorMed Inc:

PhorMed is focused on developing therapies in Oncology, Neurology, and Virology, with initial concentration in treating ARDS induced by COVID-19, AML, Hodgkin’s Lymphoma, Parkinson’s disease, and Stroke.  The Company’s goal is to give patients options where there currently are none or allow for better options. PhorMed’s study drug RP-323, or 12-O-tetradecanoylphorbol-13-acetate (TPA) aka Phorbol-12-myristate-13-acetate (PMA), is a treatment administered through I.V. infusion. The RP-323 primary mechanisms of action include (1) induction of differentiation; (2) promotes proliferation; (3) cytokine induction; (4) and/or apoptosis. Find out more at www.PhorMed.com

 


You can help today by investing and be part of bringing us one step closer to getting an ARDS Phase 2 Human Study underway, sharing our vision of bringing better medical treatment to those in need.

 

To see the full published article, please click <here>, or search “PHORMED  NEWS” on Yahoo Finance. 

 

Announcing results from our on-going ARDS study!

2 months ago




We are excited to announce, for the first time, results from our on-going preclinical studies of Acute Respiratory Distress Syndrome (ARDS). We have determined our drug RP-323 has the ability to block or limit inflammation associated with ARDS taking effect within 24 hours of administration. More detailed information will follow.

 

ARDS can develop from numerous respiratory conditions including COVID-19 and there are currently no FDA approved targeted therapies for active ARDS. Patients have the potential to rapidly develop a variety of lung inflammatory conditions including general bronchial damage, fibrosis, vascular thrombosis, double pneumonia, and in severe cases, ARDS can lead to death.

 

We thank you for following us and hope you take an active role by investing today and helping move our studies to the next phase.


All the best,

The PhorMed Family.





The final Time Based Bonus offer ends in a few hours

4 months ago

Today marks the last few hours to take advantage of the bonus share offer. The countdown clock tracking the remaining time is available in the Rewards section of our homepage.

 

If you invest before the counter hits zero, you can take advantage of the Time-Based Bonus Shares of 5%, which would be in addition to a 10% StartEngine Owner and/or Loyalty Bonus giving you a potential 15% bonus to qualified investors.

 

As we close out this last week of Bonus Shares, we want to thank all our loyal investors and encourage you to continue supporting our campaign as we move forward. Your continued support has been instrumental in our success to date.

 

 

Best regards,

 

From The PhorMed Team

Logo, company name

Description automatically generated

Final chance to take advantage of our Time Based Bonus Share offer - ends tomorrow!

4 months ago

Tomorrow marks the end of the 4th week of the Time Based Bonus Share program and the final chance to earn these bonus shares. Invest now to take advantage before time runs out.

 

If you invest now, you can take advantage of the Time-Based Bonus Shares of 5%, which would be in addition to a 10% StartEngine Owner and/or Loyalty Bonus giving you a potential 15% bonus to qualified investors.

 

Please don’t miss out on the opportunity to take advantage of these bonus shares, and feel free to share information on our technology with anyone that you feel may be interested.

 

 

Best regards,

 

From The PhorMed Team

Logo, company name

Description automatically generated

Final chance to take advantage of our Time Based Bonus Share offer - ends in a few days!

4 months ago

Your chance to earn Bonus Shares ends in a few days. Invest now to take advantage before time runs out.

 

If you invest now, you can take advantage of the Time-Based Bonus Shares of 5%, which would be in addition to a 10% StartEngine Owner and/or Loyalty Bonus giving you a potential 15% bonus to qualified investors.

 

Please don’t miss out on the opportunity to take advantage of these bonus shares, and feel free to share information on our technology with anyone that you feel may be interested.

 

 

Best regards,

 

From The PhorMed Team

Logo, company name

Description automatically generated

Week 3 Update: Over $180,000 raised!

4 months ago

We are entering the 4th week of our new campaign, and we have raised over $180,000 from our loyal investors. 

 

5% Bonus for Week 4 begins today: 

Invest now and take advantage of the Time-Based Bonus Shares of 5%, which would be in addition to a 10% StartEngine Owner and/or Loyalty Bonus giving you a potential 15% bonus to qualified investors.

 

Our goals for this year are hefty, but we can accomplish them with the help of our investors. Please visit our page and consider investing or reinvesting in our technology.

 

 

Best regards,

 

From The PhorMed Team 

Logo, company name

Description automatically generated

Last Hours for the 10% Bonus Shares!

4 months ago

As we end the 3rd week of our new campaign, these are the last few hours to take advantage of the 10% bonus offer. A running countdown of the time remaining can be found on our homepage in the Rewards section.

 

If you invest before the counter hits zero, you can take advantage of the Time-Based Bonus Shares of 10%, which would be in addition to a 10% StartEngine Owner and/or Loyalty Bonus giving you a potential 20% bonus to qualified investors.

 

 

Best regards,

 

From The PhorMed Team

Logo, company name

Description automatically generated

Tomorrow is the Last day for 10% bonus shares!

4 months ago

The chance to take advantage of 10% in bonus shares when you invest in PhorMed ends tomorrow. Make sure to check the countdown on our homepage for expiration.

 

If you invest now, you can take advantage of the Time-Based Bonus Shares of 10%, which would be in addition to a 10% StartEngine Owner and/or Loyalty Bonus giving you a potential 20% bonus to qualified investors.

 

Don’t wait to check out our new campaign page and share information on our technology.

 

 

Best regards,

 

From The PhorMed Team

Logo, company name

Description automatically generated

Week 2 Update: Over $145,000 raised!

4 months ago

As the second week of our new campaign ends, we have raised over $145,000 from our loyal investors. 

 

10% Bonus for Week 2 begins today: 

Invest now and take advantage of the Time-Based Bonus Shares of 10%, which would be in addition to a 10% StartEngine Owner and/or Loyalty Bonus giving you a potential 20% bonus to qualified investors.

 

With your help, we can accomplish the goals we have set for ourselves this year. Please consider visiting our page and investing or reinvesting in our technology to keep us moving forward.

 

 

Best regards,

 

From The PhorMed Team 

Logo, company name

Description automatically generated


15% bonus shares ends today!

4 months ago

We are at the end of the second week of our new campaign and the 15% bonus offer ends this afternoon. To see time remaining you can navigate to our homepage where a countdown can be found in the Rewards section.

 

If you invest before the counter hits zero, you can take advantage of the Time-Based Bonus Shares of 15%, which would be in addition to a 10% StartEngine Owner and/or Loyalty Bonus giving you a potential 25% bonus to qualified investors.

 

 

Best regards,

 

From The PhorMed Team

Logo, company name

Description automatically generated

15% bonus shares end tomorrow!

4 months ago

Tomorrow is the last day to receive 15% in bonus shares when you invest in PhorMed. Check the countdown on our homepage for expiration.

 

If you invest now, you can take advantage of the Time-Based Bonus Shares of 15%, which would be in addition to a 10% StartEngine Owner and/or Loyalty Bonus giving you a potential 25% bonus to qualified investors.

 

Please consider visiting our new campaign page and investing or reinvesting in PhorMed, and sharing our information with anyone you feel may have an interest.

 

 

Best regards,

 

From The PhorMed Team

Logo, company name

Description automatically generated

Over $120,000 raised in first week!

4 months ago

We have raised more than $120,000 in the first week thanks to our amazing investors. 

 

15% Bonus for 1 week starting today: 

Invest now and take advantage of the Time-Based Bonus Shares of 15%, which would be in addition to a 10% StartEngine Owner and/or Loyalty Bonus giving you a potential 25% bonus to qualified investors.

 

Your continued support will allow us to complete our milestones and accomplish our timelines quicker. Please consider passing our information onto family and friends who may have an interest in our technology.

 

 

Best regards,

 

From The PhorMed Team 

Logo, company name

Description automatically generated

20% bonus shares ends in a few hours!

4 months ago

This week’s 20% bonus offer ends in a few hours. A countdown can be found on our homepage in the Rewards section.

 

If you invest in the next few hours, you can take advantage of the Time-Based Bonus Shares of 20%, which would be in addition to a 10% StartEngine Owner and/or Loyalty Bonus giving you a potential 30% bonus to qualified investors.

 

 

Best regards,

 

From The PhorMed Team

 

20% bonus shares ends soon!

4 months ago

Tomorrow is your last opportunity to receive 20% in bonus shares when you invest in PhorMed. Check the countdown on our homepage for expiration.

 

If you invest now, you can take advantage of the Time-Based Bonus Shares of 20%, which would be in addition to a 10% StartEngine Owner and/or Loyalty Bonus giving you a potential 30% bonus to qualified investors.

 

Please don’t wait and miss out on this offer.

 

 

Best regards,

 

From The PhorMed Team

Logo, company name

Description automatically generated

LAUNCH UPDATE: PhorMed Campaign #2, May 2022

5 months ago



PhorMed is excited to announce the launch of our second StartEngine campaign!

 

If you invest now, you can take advantage of the Time-Based Bonus Shares of 20%, which would be in addition to a 10% StartEngine Owner and/or Loyalty Bonus giving you a potential 30% bonus to qualified investors.

 

Your continued support will help us reach our goals. We strive to complete some, most, or all the following items, with the funds raised this round, including but not limited to:

 

  • Manufacture batch #2 of our study drug serum, RP-323.

 

  • Complete our currently active COVID-19/acute respiratory distress syndrome (ARDS) study

 

  • Complete COVID-19 grant application and submit

 

  • Complete the patent application for the newly discovered indication #6, (details soon to be announced)

 

  • Design a pre-clinical study for indication #6 and complete the study

 

  • Continue our Parkinson’s research with our partners, Emory University and Absorption Systems (ASI), moving us closer to a Phase II study

 

  • And finally, with the help of Winship Cancer Institute at Emory University, we look to finalize our amendments to the Phase I/II AML and Hodgkin’s Lymphoma protocols and submit them to the FDA

  

Our last campaign close was very successful thanks to all our Investors. We have set hefty goals, but all can be accomplished with the proper funding and support. We would like your help expanding the PhorMed Family by introducing new investors and bring us closer to our final goals.

 

We are looking forward to an exciting year ahead.

 

Best regards,

 


 

 From The PhorMed Team


Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Please sign in to post a comment.
Please use Updates for communications.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}